Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
The company received gross proceeds of approximately US$1.7 million and net proceeds,
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Marks remarkable acceleration in innovation using AI technology
NEIAFMR to be developed as the national hub for folk medicine
The LyondellBasell CirculenRenew polymers are made from renewable feedstocks derived from bio-based wastes
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
New facility is part of Aptar Pharma’s global expansion program
Subscribe To Our Newsletter & Stay Updated
